Bristol-Myers Squibb and GlaxoSmithKline are working separately to develop a new class of drug to treat a symptom of diabetes. The drugs, called sodium glucose uptake transporter 2 inhibitors, are expected to block the normal tendency of kidneys to reabsorb excess glucose from the body instead excreting it.

Related Summaries